CRIS | tickerfilter.com

Fundamental analysis

31%

Profitability 25%

Dept financing 21%

Liquidity 68%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.46%

1 Month

-21.34%

3 Months

-37.48%

6 Months

-57.73%

1 Year

-77.44%

2 Year

542.61%

Key data

Stock price

$3.22

P/E Ratio

-0.69

DAY RANGE

$3.13 - $3.23

EPS

-$8.23

52 WEEK RANGE

$3.26 - $17.49

52 WEEK CHANGE

-$77.18

MARKET CAP

33.034 M

YIELD

N/A

SHARES OUTSTANDING

5.979 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

10/31/2024

BETA

0.36

PUBLIC FLOAT

AVERAGE 10 VOLUME

$84,653

AVERAGE 30 VOLUME

$70,311

Company detail

CEO: James E. Dentzer
Region: US
Website: curis.com
Employees: 60
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Curis, Inc. engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial. CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation.

CRIS - CURIS INC